Discussion by rheumatologists on the merits of biologics vs. triple therapy for patients with RA lends insight into therapeutic alternatives
Search results for: infliximab
Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors
Two patients with psoriatic arthritis treated with TNF-alpha inhibitor therapy develop the multisystem disease
EULAR 2013: New RA Recommendations Address Combination Therapy Concerns
Guidelines give greater nod to use of combination conventional disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis, leave monotherapy with methotrexate as acceptable first-line treatment
EULAR 2013: Drugs New and Old Could Treat Spondylarthropies
Nonsteroidal anti-inflammatory drugs (NSAIDs) might still have a role in treating axial spondylarthritis, but other drugs, therapies are being explored
RA Treatment Options Expanded with New Infusible TNF Inhibitor
FDA approves second infusible anti–tumor necrosis factor treatment for patients with moderate to severe rheumatoid arthritis. (posted Aug. 16, 2013)
When Will Generic Biologic Drugs Become Commercially Available?
Biosimilars are challenging to produce, but progress is being made
Ethics Forum: Ethics of Infusions in the Face of A Professional Conflict
An infusion prescription ordered by a rheumatologist, but changed by a hematologist, raises dilemmas concerning a patient’s continuity of care
Coding Corner Question: July
#Test your coding knowledge for subsequent infusions of infliximab
Coding Corner Answer: July Coding Challenge
Coding for a patient who gets subsequent infusions of infliximab
Dermatology Case Answer C: May
C) Tumor necrosis factor (TNF)–α-induced palmoplantar pustular psoriasis
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 38
- Next Page »